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Abstract 
Background: Guidelines for protecting young infants from pertussis now recommend maternal pertussis booster 
vaccination (dTpa) during pregnancy (3rd trimester) over postpartum maternal vaccination. 
 
Methods: We undertook a cross-sectional survey of 723 postpartum women on the postnatal ward of a private 
hospital in Sydney, Australia. We excluded 47% of women who were ‘up to date’ with their pertussis booster prior 
to pregnancy. We surveyed the remaining 53% of women who were eligible for the pertussis booster vaccine during 
their pregnancy (no dTpa<5years). 
 
Results: In our study, pertussis booster vaccine uptake during pregnancy was only 8.7%. We confirmed that 
vaccination mostly occurred at the family doctor’s practice (25/33; 75.8%), at an average of 34 weeks gestation 
(+5wks). Women vaccinated during pregnancy were more likely to report that they received a pregnancy-specific 
pertussis vaccine recommendation (<0.001), and had no vaccine safety concerns (0.004) or transport difficulties in 
accessing an immunization provider (0.032). They also had twice the odds of receiving an influenza vaccine during 
pregnancy (0.002). Additionally, 70% of vaccinated women reported that their partner had also been recently 
vaccinated against pertussis. Amongst unvaccinated women we found that 80% intended to be vaccinated, yet 33% 
would only do so if the vaccine was free (publically funded). Additionally, 40% of unvaccinated women would have 
agreed to pertussis vaccination during pregnancy had their doctor recommended it.  
 
Conclusion: Providers should highlight pertussis vaccine safety and recommend vaccination during late pregnancy. 
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Nomenclature 
ACIP  Advisory Committee on Immunization Practices 
CDC  Centre for Disease Control and Prevention 
dTpa  Diphtheria, tetanus and acellular pertussis (‘pertussis booster vaccine’)  
Family doctor  Also known as ‘general practitioner’ 
1. Introduction  
Pertussis still remains a prominent public health issue despite sustained high coverage of the primary vaccination 
series. This is due to immunization being delayed until after the newborn period, which leaves infants under 6 
months with little or no protection1. Maternal vaccination during pregnancy addresses this gap, and is recommended 
when a mother or an infant are at significant risk of disease for which a safe and effective vaccine is available2. A 
key example is vaccination against tetanus during pregnancy, resulting in a 93% reduction in deaths from neonatal 
tetanus due to high coverage (>80%) among childbearing women this decade3. Maternal immunization against 
pertussis at 30-32 weeks gestation optimizes placental antibody transfer to the fetus, which, in turn, provides some 
direct protection to the newborn4. This differs to the indirect protection afford by postpartum immunization, which 
may not provide sufficient protection to newborns due to a lag in maximal maternal antibody response (~14 days)5.  
 
Maternal vaccination during pregnancy (27-36 weeks gestation) has been recommended since 2011 by the 
Advisory Committee on Immunization Practices (ACIP) of the Centre for Disease Control and Prevention (CDC)4. 
Implementation in the USA (2011) and UK (2012) has yielded a 49%-79% uptake (4, 6, 7). Since 2013, Australian 
Immunization Guidelines have included pertussis vaccination during pregnancy8, with a media release by the State 
Ministry of Health alerting providers and the general public to this change in pertussis control9. As part of a larger 
study of the impact of education on vaccine uptake on the postnatal ward, we surveyed postpartum women for 
vaccination status during pregnancy, and associated factors. 
2. Methods  
The questionnaire formed part of the baseline data for the Maternal Pertussis Randomized Control Trial, 
approved by the North Shore Private Hospital Ethics Committee and registered with the Australia New Zealand 
Clinical Trials Registry10. Written informed consent was obtained from all participants. Details of the control trial, 
including results from the public hospital site, have been published elsewhere11. 
2.1. Patients 
From June to December 2013, we approached postpartum mothers receiving private obstetric care on the 
postnatal ward of a metropolitan hospital in Sydney, Australia. This hospital caters for around 2700 births per 
year(12). We surveyed postpartum women (<day 7 of childbirth) who were eligible for the pertussis booster vaccine 
during their pregnancy (no dTpa<5years). We excluded those who had been up to date prior to pregnancy 
(dTpa<5years). Of women who self-reported vaccination during pregnancy, we confirmed 75% by comparing with 
their family doctor vaccination records. 
2.2. Questionnaire 
Participating women completed an electronic-based knowledge and attitudes survey on an Apple iPad® (Figure 
1). It was powered by web-based survey software (Peoplepulse®) and managed by The University of Sydney 
Information Technology Department. The survey was based on the Health Belief Model (HBM) constructs13 and 
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evaluated: perceived susceptibility to contracting pertussis, severity of pertussis, barriers to vaccination, 
effectiveness of vaccination and cues to action. A univariate chi square analysis of questionnaire items and 
vaccination during pregnancy was undertaken using IBM SPSS statistics (version 22).   
 
 
Fig.1. Questionnaire items of benefits and barriers to pertussis booster vaccination, based on the Health Belief Model                                 
(enlarged text indicates a significant attitudinal differences between women vaccinated in pregnancy versus not).  
 
3. Results  
We screened 99.3% (723/728) of postpartum women approached for vaccine status (5 declined: busy/tired). We 
excluded 342 (342/723; 47.3%) women vaccinated prior to pregnancy (dTpa<5years). The remaining 381 women 
completed a baseline questionnaire, of which 33 were excluded (2 misclassification; 31 missing data). Pertussis 
vaccine uptake during pregnancy was 8.7% (33/381) and occurred at an average of 34 weeks gestation (+5.15 
weeks). We confirmed vaccine date with the family doctor for 75.8% of women reporting vaccination during 
pregnancy (1 false recall). Demographics did not differ significantly according to vaccine status, with participants 
on average aged 30-34 years, Australian-born (57.9%), English speaking (307; 88.5%) and multiparous (66%). 
3.1. Disease awareness and information sources 
Overall awareness of pertussis was high, with nearly all participants having heard of it as ‘whooping cough’ 
(336; 97.1%). Women reported that they heard of ‘whooping cough’ from an average of three information sources. 
However, we noticed that whilst women reported a range of information sources, certain sources influenced their 
choices about vaccination. Nearly all women reported that health professionals were most influential to their vaccine 
decision-making (315; 91%), followed by immunization brochures (109; 31.5%) and family or friends (86; 24.9%).  
3.2. Disease perception and knowledge 
Whilst pertussis was perceived by all participants as very infectious (308; 89%), unvaccinated participants were 
more likely to perceive pertussis as ‘rare’ in their community (44.3% vs. 20%; p=0.018) (Table 1). Most women 
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     Table 1. Disease perceptions and barriers to pertussis vaccination associated with uptake or decline during pregnancy. 
Survey item* Vaccinated (n=30)^ Unvaccinated (n=319 P value 
In my community, whooping cough is: 
Common 












Transport to a vaccine provider is a problem. 
Agree / strongly agree 
Neither agree nor disagree 











I am concerned about the vaccine’s safety. 
Agree / Strongly Agree 
Neither agree nor disagree 












^3vaccinated participants excluded (missing data); *5 item Likert scale condensed to 3 items. 
3.3. Pertussis booster vaccine attitudes and beliefs 
Participants generally agreed that pertussis booster vaccination would help prevent their baby getting whooping 
cough (321; 92.5%), and it was their parental responsibility to do so (321, 92.5%). Barriers included transport to an 
immunization provider (10% vs. 0%; p=0.032) and vaccine safety concerns (15.8% vs. 0%; p=0.004) (Table 1). 
One-third of unvaccinated women reported that they would only be vaccinated if the pertussis booster vaccine was 
funded: they would not pay to receive it.   
3.4. Vaccine recommendation 
Women vaccinated during pregnancy were significantly more likely to have received a pertussis booster 
recommendation (96.7% vs. 69.1%; p=0.001). In addition, vaccination during pregnancy was associated with the 
receipt of a pregnancy-specific pertussis booster recommendation by a health professional (91.3% vs. 37%). Among 
unvaccinated participants who were not recommended prenatal pertussis vaccination, 40.2% (53/132) would have 
agreed to vaccination during pregnancy had their doctor recommended it. Overall, 80.2% (247) unvaccinated 
women reported that they intended to have the pertussis booster vaccine (Graph 2).  
3.5. Reported partner vaccine status 
We found that women who had been vaccinated during pregnancy more frequently reported that their partner had 
also received the pertussis booster vaccine compared to unvaccinated women (70% vs. 11%; p<0.001) (Graph 2).  
3.6. Pertussis vaccination versus routine pregnancy vaccination (Influenza)  
We also asked about another vaccine which is routinely given during pregnancy. Among all women, 60.2% 
reported having been recommended the influenza vaccine during pregnancy, yet only 39.1% were vaccinated against 
influenza during pregnancy. We looked at whether this differed by pertussis vaccine uptake during pregnancy, as it 
is plausible that these women were more accepting of vaccination in pregnancy in general (rather than which disease 
they were being immunized against). We found that woman vaccinated against pertussis during pregnancy not only 
had twice the odds of having been recommended the influenza vaccine (OR: 2.7; p=0.003; 95% CI: 1.1-6), but were 
also three times as likely to have been vaccinated against influenza during pregnancy (OR: 3.1; p=0.003; 1.4-6.7) 
(Graph 2).     
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Graph 2. Survey response of participants about perinatal vaccines, stratified by pertussis vaccination during pregnancy. 
4. Discussion 
Our study reported an 8.7% (95% CI: 6%-12%) pertussis booster vaccine uptake during pregnancy among 
eligible women, at an average of 34 weeks gestation as recommended (29-36weeks) 4, 8. This increased pertussis 
vaccine coverage to 51% among all postpartum women screened for vaccine status. Women who were vaccinated 
against pertussis during pregnancy were more likely to have received a pertussis booster vaccine recommendation, 
as well as have had their health professional recommend this vaccine during pregnancy. These women who were 
vaccinated against pertussis during pregnancy also reported no vaccine safety concerns (p=0.006), held the 
perception that whooping cough was ‘common’ in their woman’s community (p=0.018), and less frequently 
reported transport barriers to accessing their family doctor to receive a vaccine (0.032). We also observed that 
women who had the pertussis vaccine during pregnancy were three times as likely to have also been vaccinated 
against influenza during pregnancy. Low uptake in pregnancy suggests that added measures may be required, in 
addition to a health wide media announcement highlighting vaccination shift to during pregnancy9. 
 
Prior to the introduction of national guidelines, we previously reported an even lower pregnancy pertussis uptake 
of 0.5% among eligible women, without any specific education or strategy14. Our current data shows that uptake in 
pregnancy has increased to 8.7% since the introduction of national guidelines recommending pertussis vaccination 
during pregnancy. However, uptake remains low compared to other countries which have systematically 
implemented this guideline or recommendation. In the UK, 49% population-wide pertussis vaccine uptake during 
pregnancy was sustained by systematically offering a free (publically funded) pertussis vaccine to women during 
routine antenatal appointments with their midwife or GP6, 15. In the Australian context, while guidelines exist, there 
is not a systematic approach to antenatal pertussis vaccination. We identified factors which suggest the role for a 
three-tiered approach to implementation: the setting, the patient and the provider.  
4.1. Setting 
Access to an immunization provider is an important consideration: women vaccinated against pertussis during 
pregnancy less frequent reported transport barriers to accessing their family doctor to receive a vaccine (0.032). This 
may be a conservative estimate, as our sample was biased to a more affluent demographic given these women could 
afford private obstetric care (25% of Australian women)12. As the majority of Australian women receiving 
midwifery care may not routinely see a doctor during pregnancy, accessing an immunization provider may be a 
greater barrier than identified by our data. This barrier to vaccination has previously been reported by 73% of 
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pregnant women receiving public obstetric care who were eligible for influenza vaccine; with uptake 29% higher in 
the prenatal clinic with a nurse dedicated to providing funded vaccination (17% vs. 46%)16. Integration of pertussis 
booster vaccination into routine antenatal settings may increase uptake.  
4.2. Patient 
In our study, over 90% of women agreed that the benefits of receiving the pertussis booster vaccine outweighed 
the risks. However, this general perception of the vaccine may differ among women in the context of pregnancy. We 
observed that women who received the pertussis vaccine during pregnancy reported no vaccine safety concerns 
(p=0.006). This suggests that vaccine ‘risk’ may be perceived by pregnant women as absolute rather than a 
continuum. This is congruent with the maternal-fetal bond, characterized by an ‘innate desire to protect’ the fetus 
through prevention of any threat17. Therefore, if pregnancy is a risk-adverse state, addressing vaccine safety 
concerns may be of greater importance than emphasizing disease risk.    
 
Women who accepted the pertussis vaccine whilst pregnant were also three times as likely to have been 
immunized against influenza during pregnancy. It may be plausible that these women were generally accepting of 
vaccination during pregnancy, rather than uptake being related to a specific vaccine. We also noted that overall 
influenza vaccine uptake was higher than pertussis vaccine uptake during pregnancy (38.3% vs. 8.7%). This may be 
due to variations in the timing of vaccine recommendations during pregnancy, with the pertussis vaccine only 
nationally recommended since 2013. However, cost needs to be considered as only the influenza vaccine is currently 
publically funded for pregnant women in Australia (and hence free of charge to women). Our data indicated that 
One third of unvaccinated women would have agreed to have pertussis vaccine in pregnancy if it were free. 
Extending funding to include the pertussis booster vaccine for pregnant women may help increase uptake during 
pregnancy.                                
4.3. Provider  
Among postpartum women, we found that health professionals were most influential to their vaccine decision-
making (91%), followed by immunization brochures (31.5%) and family/friends (25%). The overarching influence 
of health professionals may be attributed to the model of obstetric care (private obstetrician) that is offered in the 
private sector. Prior research in the public setting showed that an obstetrician has a lesser role (49%)18. In our study, 
nine out of ten vaccinated women were recommended the pertussis booster vaccine during their recent pregnancy. 
This differed significantly to unvaccinated women, who were less likely to have been recommended a pertussis 
booster vaccine during their pregnancy. There is scope for improvement in pregnancy pertussis vaccination uptake 
where there is an increase in provider recommendations as 40% of unvaccinated women in our sample reported that 
they would have received the pertussis vaccine during pregnancy if their doctor had recommended it. We also 
observed that a pertussis vaccine recommendation during pregnancy was more frequently reported to have been 
given by an obstetrician (47%), than a general practitioner (GP) (20%) or midwife (16%), in this private sector 
setting. Patient-provider vaccination communication during pregnancy is clearly important for vaccination uptake in 
general, as has been demonstrated with influenza vaccine uptake 18, 19. Provision of a pregnancy-specific 
recommendation by any health professional is likely to increase pertussis vaccine uptake during pregnancy. 
 
It is difficult to make definitive conclusions from the findings of this study or to generalise to other populations. 
This was a post-hoc analysis of baseline data from the Maternal Pertussis Randomized Control Trial 10. Participants 
were only women receiving private obstetric care. It is likely that pertussis vaccine uptake would be lower among 
pregnant women across Australia, and in non-English-speaking populations.  
Conclusion 
We found that pertussis booster vaccine uptake during pregnancy among eligible women was low at just under 9%, 
despite high awareness of ‘whooping cough’. To improve uptake, health professionals should systematically 
recommend the vaccine to eligible women as a routine part of their antenatal care; providers should also carefully 
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explore and address any vaccine safety concerns. Funding the pertussis vaccine for pregnant women and utilizing 
the prenatal clinic or obstetricians rooms as an immunization platform may minimize barriers to vaccination within 
the Australian health system. In our larger study, we demonstrated that a funded postpartum vaccination program 
with education and nurse recommendation yielded a 70% uptake in the postnatal ward setting11, hence this 
alternative needs continued support until high coverage during pregnancy can be achieved.  
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